# Dalteparin, Lenalidomide, and Low-Dose Dexamethasone in Treating Patients With Previously Untreated Multiple Myeloma

> **NCT01518465** · PHASE2 · TERMINATED · sponsor: **University of Southern California** · enrollment: 13 (actual)

## Conditions studied

- Stage I Multiple Myeloma
- Stage II Multiple Myeloma
- Stage III Multiple Myeloma

## Interventions

- **DRUG:** dalteparin
- **DRUG:** lenalidomide
- **DRUG:** dexamethasone
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT01518465
- **Lead sponsor:** University of Southern California
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-01-09
- **Primary completion:** 2016-12-31
- **Final completion:** 2017-10-31
- **Target enrollment:** 13 (ACTUAL)
- **Why stopped:** Insufficient Accrual
- **Last updated:** 2017-11-29

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01518465

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01518465, "Dalteparin, Lenalidomide, and Low-Dose Dexamethasone in Treating Patients With Previously Untreated Multiple Myeloma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01518465. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*